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Development and validation of a revised 
instrument to measure burden of long-term 
medicines use: the Living with Medicines 




Medway School of Pharmacy, The 
Universities of Greenwich and Kent, 
Chatham Maritime, UK
Objectives: To revise the Living with Medicines Questionnaire version 2 (LMQ-2), which 
measures the burden of using prescribed medicines, to include cost and expand side effects 
and social issues.
Methods: New statements were developed and validated through cognitive interviews with 
medicine users, and these and a global visual analog scale (VAS) were added to the 42-item 
LMQ-2. Construct validity was assessed through exploratory and confirmatory factor analyses 
using an online public survey. Criterion-related validity was measured against the Treatment 
Satisfaction Questionnaire with Medication (TSQM-II) and the EuroQoL 5-level quality of life 
measure (EQ-5D-5L), in patients using community pharmacies, general practices, and outpatient 
clinics. Reliability was assessed by test–retest using online public distribution.
Results: The 58-item interim instrument (n=729) was reduced to 41 items after factor analysis, 
which confirmed an eight-domain structure: relationships with health professionals, practicalities, 
interferences, effectiveness, side effects, concerns, cost, and autonomy, constructed as medicine 
burden. All subscales, except autonomy, were loaded onto this construct and showed acceptable 
internal consistency. LMQ-VAS correlated with total LMQ scores (r=0.571). Criterion validation 
(n=422) demonstrated total LMQ scores negatively correlated with TSQM scores for global 
satisfaction (r=– 0.616); domain scores showed similar correlations: effectiveness (r=–0.628), 
side effects (r=–0.597), and practicalities (r=–0.529). Total LMQ score was negatively correlated 
with EQ VAS (r=–0.383) and showed weak/moderate relationships with individual EQ-5D-5L 
dimensions. Test–retest (n=30) reliability showed intra-class correlation coefficients of 0.954 
(total LMQ score), 0.733–0.929 (domain scores), and 0.789 (global item).
Conclusion: The LMQ version 3 (LMQ-3) instrument has acceptable construct, criterion-
related and known-groups validity, and is internally consistent as a measure of medicine burden, 
although reliability requires further confirmation. It could be used to measure the outcome of 
interventions designed to reduce the burden of polypharmacy.
Keywords: medicine burden, patient experience, polypharmacy, long-term conditions
Introduction
Polypharmacy, defined as the use of multiple medicines on a daily basis by an indi-
vidual, is a growing phenomenon worldwide, due to increases in life expectancy and 
the prevalence of chronic medical conditions such as cardiovascular disease, type 2 
diabetes, arthritis, osteoporosis, and the increasing use of medicines to manage these 
conditions.1 However, while the number of medicines is potentially an indicator of the 
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frequency with which problems such as drug interactions may 
occur,2 the patient experience of using multiple medicines is 
often overlooked.3 Yet, it is increasingly recognized that the 
treatments imposed on individuals by health professionals can 
be burdensome. Treatment burden, which covers everything 
patients do to take care of their health,4 for most patients 
includes managing one or more medicines.5
From the biomedical perspective, “problematic polyphar-
macy” has been defined as “multiple medications prescribed 
inappropriately, or where the intended benefit of the medi-
cation is not realized,”6 and a range of interventions have 
developed which could be used to reduce the number of medi-
cines and optimize their use.7,8 A key element of optimizing 
medicine use in individual patients is the need to understand 
their experience, including any difficulties and concerns. In 
England, both the Medicines Optimisation Strategy, devel-
oped by the Royal Pharmaceutical Society,9 and other national 
guidance10 emphasize the need to determine the patient 
experience as the first stage in this process. Patients’ attitudes 
toward and experiences with using medicines (positive and 
negative), their attempts at experimentation and prioritizing, 
together with issues relating to obtaining medicines and their 
relationship to prescribers all contribute to the success of any 
intervention aiming to reduce problems with medicines.11,12 
A means of quantifying the patient’s individual medicine 
experience is thus essential for practice, while appropriate 
outcome measures are also necessary for evaluating inter-
ventions. However, there are few patient-reported outcome 
measures available which focus solely on medicine use and 
which thus have the potential to demonstrate change follow-
ing interventions designed to reduce problems with medicines 
in patients using polypharmacy.13,14 
We have developed an instrument designed to measure 
the patient experience of long-term polypharmacy concep-
tualized as medicine burden, the Living with Medicines 
Questionnaire version 2 (LMQ-2).15 This instrument, unlike 
most other patient-reported measures, was developed from 
the patient perspective.16 The instrument consists of 42 state-
ments accompanied by a 5-point Likert-type scoring system. 
Eight domains were identified through factor analysis, 
relating to: perceptions about effectiveness, concerns about 
medicine use, patient–provider relationships and communica-
tion about medicines, practical difficulties, interferences to 
daily life, autonomy/control over medicine, and acceptance 
of medicine use, all areas which have been cited by users of 
long-term medicines as burdensome.15 
Some respondents to this instrument identified that it 
lacked a domain covering cost burden, which can be an 
issue of concern to some patients, even in countries with 
good access to free medicines.17–19 Cost burden has also been 
recognized as potentially important in the measurement of 
overall treatment burden.4 Other respondents suggested that 
greater emphasis needed to be placed on the social aspects 
of using medicines and experiences of side effects. Review 
of the 42 statements included in the LMQ-2 showed that the 
two covering social aspects were indeed limited and the two 
covering side effects did not emphasize the effect of these on 
daily life. We therefore set out to develop a revised version 
of this instrument, which addressed these issues more fully, 
without enlarging it, and to undertake a rigorous validation 
of the revised instrument. 
Methods
Item generation and content validation
New content was based on reanalysis of the 21 patient 
interviews used to elicit concepts in the original LMQ20 and 
free-text comments from survey participants completing this 
version of the instrument,15 along with qualitative studies 
reported in the literature.12,21–23 All items were reviewed and 
new items added through discussions among the research-
ers (BK, SC, JK). An interim instrument, which included 58 
items (LMQ-2.1), was developed and assessed for face and 
content validity through cognitive interviews with long-term 
medicine users, recruited via a public engagement group. 
Members of the group who met the inclusion criteria (18 
years or older, using regular prescription medicines, able to 
read and communicate in English, and living in England) 
participated themselves and/or recruited other eligible par-
ticipants through snowballing. 
Study instruments
The interim version (LMQ-2.1) was similar to the LMQ-2, 
but contained 58 statements, rated on a 5-point Likert-type 
scale (strongly agree to strongly disagree), utilizing reverse 
scoring as appropriate with higher scores reflecting worse 
experiences of medicine use (higher medicine burden). A 
10 cm visual analog scale (VAS) was also included as a 
global item, with anchors indicating “no burden at all” to 
“extremely burdensome”, to assess the overall medicine 
burden (VAS-burden). Participant characteristics gathered 
included general demographics as well as number, frequency, 
and type of formulation of regular medicines and support 
with using medicines. The process of assessing construct 
validity in Stage 1 resulted in item reduction; therefore, the 
instrument used for Stages 2 and 3 (LMQ-3) differed in the 
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Living with Medicines Questionnaire version 3
The instruments used to assess criterion-related validity 
of the LMQ-3 were the Treatment Satisfaction Question-
naire with Medication (TSQM-II), an 11-item instrument 
which measures satisfaction with prescription medicines in 
four subscales (effectiveness, side effects, convenience, and 
global satisfaction), and the EuroQoL 5-level quality of life 
measure (EQ-5D-5L). The latter is a widely used five-item 
measure of health-related quality of life (HRQoL), including 
a VAS which measures overall health status. Permission to 
use the TSQM-II and the EQ-5D-5L (UK English versions) 
was granted by the Quintiles group (Inc) and the EuroQol 
Research Foundation, respectively.
Psychometric testing 
Different groups of participants were involved in psychomet-
ric testing of the LMQ, which was done over three stages. 
All participants were required to answer screening questions 
to ensure they met inclusion criteria stated earlier before 
completing the instrument. Consent was implied by return of 
completed paper questionnaires or electronic submission of 
online responses. IBM SPSS version 22 and AMOS version 
22 were used for statistical analyses.
Construct validity and internal consistency (Stage 1)
This used an online survey, publicized via social media, 
including Twitter and Facebook posts through UK patient 
organizations, and health websites which permitted access to 
their memberships. A missing data analysis was undertaken, 
then respondents who had completed all 58 items (LMQ-2.1) 
were included in exploratory (EFA) and confirmatory factor 
analyses (CFA) to elucidate and confirm the underlying factor 
structure of the instrument. The sample was split randomly 
into two and both subsamples were assessed for normality 
prior to use in EFA and CFA. Sample size adequacy for factor 
analyses was examined via Kaiser–Meyer–Olkin Measure 
(KMO) and by the number of items per response, though 
there is no universally accepted method.24 Bartlett’s Test of 
Sphericity and Pearson’s correlation matrix were used to 
assess factorability of data and potential multi-collinearity. 
All 58 items (LMQ-2.1) were initially subjected to principal 
axis factoring, using oblique factor rotation (promax) on 
the basis that domains were inter-related. Kaiser’s criterion 
(eigenvalues >1), scree plots, and parallel analysis were used 
to determine the number of factors for EFA. 
Criteria for item reduction were: low communalities 
(<0.3), poor loadings on the primary factor (<0.32), and/
or cross loading (>0.4) on two or more factors.25–27 Items 
loading on unstable (weak) factors, which had fewer than 
three items, and items with floor and ceiling effects were 
considered for removal, the latter defined as having skewness 
and kurtosis values above two or over 65% selecting either 
of the extreme options. 
The second half of the dataset was subjected to CFA to 
test a higher-order (second-order) model involving only the 
remaining items, using maximum likelihood estimation, based 
on the strength of correlations among domains derived from 
the EFA, and preliminary testing of a first-order model. We 
hypothesized that medicine burden could explain the variation 
among all domains within the LMQ. Goodness-of-fit indices 
used to assess the second-order model were: relative chi-square 
(chi-square statistic/degrees of freedom), root mean square 
error of approximation (RMSEA) with 90% confidence inter-
val (90% CI), comparative fit index (CFI), and Tucker–Lewis 
index (TLI). The magnitude and direction of factor loadings 
was also examined to ascertain the relative contribution of 
different items and/or domains to the models.28,29
In addition, LMQ total scores were compared to scores 
from the VAS, “Overall, how much of a burden do you feel 
your medicines are to you?” using Pearson’s correlation 
coefficient to add further to construct validation. Cronbach’s 
α was examined to assess the internal consistency of the 
LMQ-3 subscales.
Criterion-related validity (Stage 2)
The LMQ-3 together with two other relevant measures, the 
TSQM-II30,31 and a HRQoL measure (EQ-5D-5L),32 were 
distributed by hand to patients in community pharmacies, 
general practices, and hospital outpatient waiting areas. 
Spearman’s correlation coefficients were used to assess 
relationships between the three instruments, with coefficients 
<0.35 interpreted as weak, 0.35–0.5 as moderate, and >0.5 
as strong, taking a p-value of 0.05 as representing statisti-
cal significance.33 A negative relationship between overall 
medicine burden and treatment satisfaction (measured with 
the TSQM-II) was hypothesized, and LMQ-3 domain scores 
for side effects, lack of effectiveness, and practical difficul-
ties were predicted to show negative correlations with scores 
on the TSQM-II global satisfaction, satisfaction with side 
effects, satisfaction with effectiveness, and satisfaction with 
convenience subscales. Medicine burden was hypothesized 
to be negatively, but weakly, related to overall health status 
(measured with the EQ VAS), since the two constructs were 
hypothesized as being distinct.
Known-groups validity
The same population was used to assess known-groups valid-
ity, using the demographic data contained in the LMQ-3. 
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tively with regimen complexity, particularly the number of 
medicines, frequency of administration, and the formulation 
used. The need for social support with managing medicines 
was also predicted to indicate higher medicine burden. In 
addition, cost burden was hypothesized to be associated with 
having to make co-payments for prescribed medicines and 
living in areas of higher relative deprivation. Relationships 
were assessed using independent samples t-tests or one-way 
analysis of variance.
Testretest reliability (Stage 3)
This was assessed using online distribution to a cohort of 
the general public who had signed up to a research unit, with 
the instrument redistributed to respondents after 2 weeks. 
Stability of scores was assessed for subscales (domains), the 
LMQ-3 total score, and the global VAS score using intra-class 
correlation coefficients (ICCs) and their 95% confidence 
intervals, which were estimated by using the two-way mixed 
effects model for absolute agreement where rater effects were 
assumed constant, with an ICC value of ≥0.7 considered as 
acceptable.34 
Missing data analysis
The patterns of missing responses to Stage 1 and Stage 2 
were assessed, and for Stages 2 and 3, the demographic 
characteristics of those with partial responses compared to 
those who fully completed the LMQ-3, using chi-squared 
tests, where appropriate.
Ethical approval
Approval was obtained from the Medway School of Phar-
macy research ethics committee for studies involving 
the general public (instrument revision, Stages 1 and 3). 
Approval for stage 2 was granted from the National Health 
Service research ethics committee South Central Oxford C 
and relevant research governance obtained. All procedures 
performed were in accordance with the ethical standards of 
the institutional or national research committee and with 
the 1964 Helsinki Declaration and its later amendments or 
comparable ethical standards.
Results
Completion rates and participant 
demographics
Eleven participants, six of whom were male, aged 42–75 
years and using between 1 and 12 regular medicines 
 participated in the cognitive interviews. Recruitment was 
terminated after the 11th interview, as no new problems with 
the revised instrument emerged from the interviews, which 
showed similarities in interpretation of questionnaire items 
and general concepts underpinning the LMQ and no unique 
item meanings (i.e., data saturation). There were no major 
comprehension problems, and most participants understood 
the concept of the term burden as used in the VAS.
The few minor uncertainties which arose were resolved 
through discussions among the team, and revisions were 
made to item wording. 
The details of respondent numbers for the remainder of 
the study are shown in Figure 1. A total of 1223 individuals 
accessed the online survey in Stage 1 over a 3-month period, 
of whom 361 did not respond to any questions at all. The 729 
participants who fully completed all 58 items (59.6% comple-
tion rate) were divided into two samples for EFA (366) and 
CFA (363). For Stage 2 (criterion-related validation), 1306 
questionnaires were distributed: 220 in GP practices, 150 in 
community pharmacies, and 936 in outpatient clinics. Overall, 
422 completed questionnaires were returned, representing a 
32.3% completion rate, 36.4% (n=80), 44.7% (n=67), and 
29.4% (n=275) for GP practices, community pharmacies, and 
outpatient clinics, respectively. Item-level completion rates 
were high (91.9%–100%), with 336 (79.6%) fully completing 
all 41 Likert-type statements. The Stage 3 invitation to com-
plete the test–retest questionnaire was sent to ∼300 members 
of a research unit; however, no data were available on the 
proportion of the members eligible for this stage. Forty-five 
people responded: 35 (78%) completed the baseline question-
naire and 30 (86%) fully completed the retest questionnaire. 
Demographic details of all the three participant groups 
are shown in Table 1. Overall, more than half of all partici-
pants were female, the majority were white and the number 
of medicines used was similar among all groups, the highest 
number used being 26. The patients involved in assessing 
criterion-related and known-groups validity (Stage 2) were 
older and had lower education levels than the public who 
were involved in the factor analysis study (Stage 1). There 
were sufficient numbers of respondents in Stage 2 who used 
medicines more than once a day, needed support from others 
to manage their medicines, and had to pay for their medicines 
to enable assessment of known-groups validity.
Construct validity and internal 
consistency (Stage 1)
Responses to individual LMQ items were normally dis-
tributed, all having skewness values <2.0; only five items 
had skewness values >2. Potential floor/ceiling effects were 
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Living with Medicines Questionnaire version 3
of respondents selecting the lowest scoring option. The 
EFA sample size (n=366) met the minimum requirements 
for factor analysis of at least five participants per item, a 
KMO value of 0.902 (acceptable values ≥0.6) and Bartlett’s 
Test of Sphericity being significant (chi-square =10,585.7, 
df=1653; p<0.001).35 All inter-variable correlations were 
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<0.8, and there was thus no evidence of multi-collinearity 
(or redundancy) among items. Conversely, most correlations 
were >0.3, indicating sufficient commonality to justify the 
presence of underlying factors. 
The initial EFA solution resolved into 13 factors with 
eigenvalues >1, explaining 63.4% of the total variance. The 
scree plot suggested retention of eight factors, while  parallel 
analysis revealed seven factors met statistical inclusion 
 criteria. An eight-factor solution was most stable and concep-
tually interpretable. The eight factors were termed: interfer-
ences with day-to-day life, relationships and communication 
about medicines, lack of effectiveness, general concerns about 
medicines, side effects, practical difficulties, cost-related 
burden, and lack of autonomy/control of medicine use. 
Table 1 Characteristics of study participants
Stage 1 Stage 2 Stage 3 








n (%) n (%)
Gender Female 312 (86.7) 300 (85.0) 208 (52.8) 20 (67)
Male 48 (13.3) (n=360) 53 (15.0) (n=353) 186 (47.2) (n=394) 10 (33) (n=30)
Age group (years) 1829 25 (7.0) 26 (7.3) 51 (12.1) 1 (3)
3049 155 (43.2) 159 (45.0) 81 (19.3) 1 (3)
5064 153 (42.6) 137 (38.7) 118 (28.1) 5 (17)
≥65 26 (7.2) (n=359) 32 (9.0) (n=354) 170 (40.5) (n=420) 23 (77) (n=30)
Education level School 73 (20.5) 66 (18.7) 158 (40.3) 5 (17)
Technical college 86 (24.2) 93 (26.3) 117 (29.9) 5 (17)
University 161 (45.2) 168 (47.6) 89 (22.7) 17 (57)
Other 36 (10.1) (n=356) 26 (7.4) (n=353) 28 (7.1) (n=392) 3 (10) (n=30)
Employment status Employed 163 (45.8) 168 (47.5) 159 (38.8) 5 (17)
Unemployed 36 (10.1) 48 (13.5) 44 (10.7) 0 (0)
Retired 67 (18.8) 59 (16.7) 187 (45.6) 23 (77)
Full-time student 10 (2.8) 10 (2.8) 20 (4.9) 0 (0)
Other 80 (22.5) (n=356) 69 (19.5) (n=354) 0 (n=410) 2 (7) (n=30)
Ethnicity White 345 (96.1)  339 (95.8) 353 (86.5) 29 (97)
Asian/Asian British 3 (0.8) 3 (0.8) 15 (3.7) 0 (0)
Mixed 1 (0.3) 6 (1.7) 10 (2.4 1 (3)
Black/African/Caribbean 2 (0.6) 2 (0.6) 26 (2.4) 0 (0)
Other 8 (2.2) (n=359) 4 (1.1) (n=354) 4 (1.0) (n=408) 0 (0) (n=30)
Number of medicines 14 220 (61.1) 212 (59.9) 236 (56.7) 16 (53)
59 107 (29.7) 112 (31.6) 126 (30.3) 14 (47)
≥10 33 (9.2) (n=360) 30 (8.5) (n=354) 54 (13.0) (n=416) 0 (0) (n=30)
Formulation usedc Tablets/capsules 349 (95.3) 343 (94.5) 374 (92.6) 28 (93)
Any other formulation 151 (41.2) (n=366) 166 (45.7) (n=363) 120 (29.7 (n=404) 16 (53)
Frequency of  
medicine usec
Once daily 160 (43.7) 169 (46.5) 146 (35.9) 18 (60)
Twice daily 151 (41.2) 134 (36.9) 136 (33.5) 10 (33)
Three times daily 76 (20.8) 73 (20.1) 49 (12.1) 6 (20)
≥4 times daily 55 (15.0) 65 (17.9) 47 (11.6) 1 (3)
Other timesa 50 (13.7) (n=366) 54 (14.9) (n=363) 28 (6.9) (n=406) 2 (7)
Assisted in using 
medicines
No - independent 306 (85.2) 309 (87.3) 349 (85.7) 29 (97)
Yes - has a caretaker 53 (14.8) (n=359) 45 (12.7) (n=354) 58 (14.3) (n=407) 1 (3) (n=30)
Spouse/partner 34 (64.2) 33 (73.3) 33 (58.9) 1 (3)
Relative 9 (17.0) 1 (2.2) 10 (17.9) 0 (0)
Support worker 4 (7.5) 3 (6..7) 7 (12.5) 0 (0)
Friend 1 (1.9) 1 (2.2) 4 (7.1) 0 (0)
Otherb 5 (9.4) (n=53) 7 (15.6) (n=45) 2 (3.6) (n=56) 0 (0) 
Pays for prescriptions No 245 (68.1) 248 (70.1) 267 (66.6) 27 (90)
Yes 115 (31.9) (n=360) 106 (29.9) (n=354) 141 (33.4) 3 (10) (n=30)
Notes: aIncludes medicines PRN, different times of the week, fortnightly, monthly, every 3 months; bincludes nurse or multiple support from relatives, friends, and caretakers. 
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Living with Medicines Questionnaire version 3
A total of 17 items were deleted from the preliminary 
58-item pool after exploratory factor analysis, leaving a 
41-item questionnaire (LMQ-3). Table 2 shows the 41 LMQ-3 
items retained and the eight-factor structure.
The sample of 363 was adequate for CFA, and multi-
variate normality was acceptable as judged by Mardia’s 
coefficient (171.6, critical ratio =27.5). First-order factor 
loadings were in the range of 0.396–0.891 and were statisti-
cally significant (p<0.001) for all items. CFA confirmed 
inter-correlations among factors underlying the LMQ-3, 
although “autonomy” was least correlated with other factors. 
In the hypothesized second-order model (Figure 2), factor 
loadings were in the range of 0.32–0.88 and statistically 
significant (p<0.001) for seven domains, being strongest for 
“interferences” (0.88), “side effects” (0.85), and “concerns” 
(0.81). “Autonomy” did not load significantly on medicine 
burden (0.11, p=0.224), but empirical attempts to exclude it 
were unable to significantly improve overall model fit and 
the domain was retained based on professional judgment. 
Relative chi-square values (2.083, acceptable value <3) and 
RMSEA coefficients (0.055, 90% CI 0.051–0.058, acceptable 
value <0.06) depicted an adequate model fit, although the TLI 
and CFI values of 0.866 and 0.874, respectively, were very 
slightly below the target of ≥0.90.
All LMQ-3 subscales, except for “autonomy”, showed 
acceptable internal consistency (Cronbach’s α coefficients 
>0.7) (Table 2). A positive correlation was found between 
LMQ total scores and VAS burden scores (r=0.571, p<0.001).
Criterion-related validity (Stage 2)
The correlation between scores on the LMQ-3 total scale and 
the global satisfaction scale of the TSQM-II was strong and 
negative (r=–0.616) as hypothesized, confirming that higher 
medicine burden was associated with lower satisfaction 
(Table 3). As predicted, correlations were strongest between 
thematically comparable subscales of the two instruments: 
LMQ-3 lack of effectiveness with TSQM-II satisfaction 
with effectiveness (r=–0.628); LMQ-3 side effect burden 
with TSQM-II satisfaction with side effects (r=–0.597); and 
LMQ-3 practical difficulties with TSQM-II satisfaction with 
convenience of medicine use (r=–0.529). 
Correlations between LMQ-3 total score and EQ-5D-5L 
scores ranged from 0.284 to 0.436 (p<0.01), depicting weak 
to moderate relationships between medicine burden and 
individual HRQoL dimensions, the weakest correlation 
being for self-care and the strongest for anxiety/depression. 
LMQ-3 total score was negatively associated with general 
health status reported on the EQ VAS (r=–0.383; p<0.01), 
as hypothesized. 
Known-groups validity
There were statistically significant differences in mean 
LMQ-3 total scores dependent on the number of medicines 
used, frequency of daily medicine taking, and need for sup-
port with managing medicines (Table 4). Age and employ-
ment status were not predicted to affect LMQ-3 total scores, 
but data showed that older people perceived themselves to 
have lower medicine burden than younger participants, while 
higher scores were also seen in those who were unemployed. 
One factor contributing to this latter finding was cost burden, 
which was higher in the unemployed (mean ± SD 8.8±3.2) 
compared to those employed (mean ± SD 7.3±3.2) (p<0.05).
Total LMQ scores were also higher in those who made a co-
payment for prescription medicines.
Testretest reliability (Stage 3)
The median test–retest duration was 15 days. All eight domain 
scores had satisfactory ICC values ranging from 0.733 to 
0.929. The total LMQ-3 score was highly correlated between 
test and retest (r=0.91), mean scores being 91.07±18.92 and 
92.14±19.55, respectively, and the ICC value being 0.954. In 
addition, the global item had an ICC of 0.789.
Missing data analysis
The online survey used for Stage 1 showed a pattern of 
non-response that was directly related to the length of the 
58-item LMQ-2.1 instrument and its online presentation of 
4–5 questions per page (Figure 3). For Stage 2, there were 86 
respondents who partially completed the LMQ-3 (Figure 3); 
the most frequently omitted questions are shown in Table 5. 
The majority of missing responses could be due to the view 
that the statement was of no direct relevance, as there were 
44 who missed at least one question covering cost burden, 
and 18 who only omitted questions from this domain. How-
ever, the pattern also suggests that the length of the LMQ-3 
was also a potential reason for failure to fully complete the 
questionnaire. The 86 partial responders were younger, more 
highly educated, and using fewer medicines than the 336 who 
fully completed the LMQ-3 (Table 6). The respondents who 
failed to complete the second questionnaire in Stage 3 were 
similar in age, education, employment status, and number of 
medicines used to those who did, but three of the five were 
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Table 2 EFA-derived factor structure of the LMQ-3 (N=366)
Items Derived factors
Int Relat Effec Conc SideE Prac Cost Auto
Interferences with day-to-day life (a=0.865)
My medicines interfere with my social relationships. 0.892 0.060 0.009 0.121 0.002 0.001 0.062 0.018
My medicines interfere with my social or leisure activities. 0.779 0.078 0.022 0.139 0.015 0.052 0.079 0.000
Taking medicines affects my driving. 0.690 0.045 0.064 0.030 0.034 0.039 0.002 0.023
Taking medicines causes me problems with daily tasks (such as work, 
housework, hobbies).
0.644 0.025 0.052 0.112 0.319 0.105 0.066 0.014
My medicines interfere with my sexual life. 0.643 0.036 0.006 0.036 0.056 0.011 0.088 0.023
My life revolves around using my medicines. 0.480 0.034 0.078 0.089 0.102 0.066 0.052 0.023
Patientdoctor relationships and communication about medicines (a=0.870)
My doctor(s) listen to my opinions about my medicines. 0.032 0.810 0.051 0.018 0.028 0.048 0.042 0.047
My doctor(s) take my concerns about side effects seriously. 0.059 0.794 0.015 0.061 0.009 0.066 0.042 0.002
I get enough information about my medicines from my doctor(s). 0.049 0.761 0.000 0.094 0.033 0.025 0.014 0.043
The health professionals providing my care know enough about me and 
my medicines.
0.001 0.612 0.133 0.044 0.051 0.085 0.048 0.033
I trust the judgment of my doctor(s) in choosing medicines for me. 0.001 0.556 0.152 0.027 0.007 0.137 0.031 0.085
Lack of effectiveness (a=0.851)
My medicines are working. 0.142 0.026 0.882 0.004 0.072 0.007 0.067 0.083
My medicines live up to my expectations. 0.043 0.062 0.711 0.084 0.066 0.057 0.040 0.064
,DPVDWLVÀHGZLWKWKHHIIHFWLYHQHVVRIP\PHGLFLQHV 0.026 0.061 0.719 0.054 0.078 0.032 0.071 0.018
7KHVLGHHIIHFWVDUHZRUWKLWIRUWKHEHQHÀWV,JHWIURPP\PHGLFLQHV 0.151 0.173 0.601 0.046 0.077 0.225 0.062 0.040
My medicines prevent my condition getting worse. 0.247 0.044 0.523 0.144 0.142 0.160 0.046 0.134
My medicines allow me to live my life as I want to. 0.345 0.106 0.525 0.017 0.084 0.023 0.087 0.007
General concerns about medicines (a=0.796)
I am concerned about possible damaging long-term effects of taking 
medicines.
0.086 0.008 0.020 0.648 0.270 0.035 0.067 0.076
I worry that my medicines may interact with each other. 0.004 0.073 0.128 0.639 0.165 0.061 0.018 0.003
I am concerned that I am too reliant on my medicines. 0.167 0.043 0.028 0.635 0.173 0.099 0.037 0.096
I worry that I have to take several medicines at the same time. 0.056 0.091 0.061 0.550 0.003 0.135 0.126 0.091
I am concerned that my medicines interact with alcohol. 0.339 0.069 0.015 0.505 0.171 0.169 0.060 0.158
I feel I need more information about my medicines. 0.014 0.252 0.036 0.544 0.058 0.010 0.022 0.016
I would like more say in the brands of medicines I use. 0.196 0.200 0.081 0.447 0.134 0.005 0.076 0.009
Side effects (a=0.901)
The side effects I get from my medicines are bothersome. 0.131 0.099 0.072 0.054 0.812 0.063 0.027 0.024
The side effects I get from my medicines interfere with my day-to-day life 
(e.g., work, housework, sleep).
0.355 0.023 0.014 0.026 0.687 0.072 0.031 0.009
The side effects I get are sometimes worse than the problem for which I 
take medicines.
0.051 0.029 0.078 0.030 0.647 0.016 0.042 0.007
The side effects I get from my medicines adversely affect my well-being. 0.346 0.019 0.020 0.016 0.612 0.040 0.028 0.013
3UDFWLFDOGLIÀFXOWLHVa=0.738)
,ÀQGJHWWLQJP\SUHVFULSWLRQVIURPWKHGRFWRUGLIÀFXOW 0.093 0.225 0.110 0.148 0.089 0.734 0.060 0.061
It is easy to keep to my medicines routine. 0.044 0.079 0.174 0.065 0.024 0.631 0.009 0.018
,ÀQGJHWWLQJP\PHGLFLQHVIURPWKHSKDUPDFLVWGLIÀFXOW 0.017 0.090 0.111 0.033 0.041 0.616 0.090 0.023
I am comfortable with the times I should take my medicines. 0.048 0.093 0.323 0.024 0.024 0.398 0.031 0.010
I have to put a lot of planning and thought into taking my medicines. 0.295 0.092 0.116 0.169 0.145 0.464 0.036 0.000
I am concerned that I may forget to take my medicines. 0.170 0.139 0.056 0.343 0.162 0.421 0.139 0.172
,ÀQGXVLQJP\PHGLFLQHVGLIÀFXOW 0.311 0.020 0.028 0.102 0.086 0.410 0.021 0.102
Cost-related burden (a=0.801)
I have to pay more than I can afford for my medicines. 0.081 0.039 0.029 0.028 0.062 0.004 0.838 0.032
I sometimes have to choose between buying basic essentials or medicines. 0.130 0.002 0.109 0.057 0.016 0.013 0.704 0.050
I worry about paying for my medicines. 0.071 0.021 0.102 0.165 0.026 0.132 0.679 0.004
Lack of autonomy/control of medicine use (a=0.692)
I can choose whether or not to take my medicines. 0.051 0.036 0.005 0.000 0.012 0.029 0.020 0.732
I can vary the dose of the medicines I take. 0.102 0.008 0.086 0.179 0.089 0.035 0.033 0.668
I can vary the times I take my medicines. 0.050 0.058 0.000 0.051 0.021 0.085 0.018 0.628
Notes:$OOLWHPVDUHVFRUHGVRWKDWKLJKHUVFRUHVUHÁHFWZRUVHH[SHULHQFHVKLJKHUEXUGHQZLWKPHGLFLQHXVH6WDWLVWLFDOO\VLJQLÀFDQWYDOXHVDUHVKRZQLQEROG
Abbreviations: LMQ-3, Living with Medicines Questionnaire version 3; EFA, exploratory factor analyses; Int, interferences with day-to-day life; Relat, patientdoctor 
UHODWLRQVKLSVDQGFRPPXQLFDWLRQDERXWPHGLFLQHV(IIHFODFNRIHIIHFWLYHQHVV&RQFJHQHUDOFRQFHUQVDERXWPHGLFLQHV3UDFSUDFWLFDOGLIÀFXOWLHV6LGH(VLGHHIIHFWV&RVW
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Living with Medicines Questionnaire version 3
Figure 2 Hierarchical CFA model for the 41-item Living with Medicines Questionnaire version 3. 
Notes: Standardized path estimates are shown.
Abbreviations: &)$ FRQÀUPDWRU\ IDFWRU DQDO\VHV ,QW LQWHUIHUHQFHV ZLWK GD\WRGD\ OLIH 6LGH( VLGH HIIHFWV &RQF JHQHUDO FRQFHUQV DERXW PHGLFLQHV (IIHF ODFN RI
HIIHFWLYHQHVV3UDFSUDFWLFDOGLIÀFXOWLHV5HODWSDWLHQW²GRFWRUUHODWLRQVKLSVDQGFRPPXQLFDWLRQDERXWPHGLFLQHV&RVWFRVWUHODWHGEXUGHQ$XWRODFNRIDXWRQRP\FRQWURO
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This paper describes a revised version of a measure of overall 
medicine experiences, conceptualized as medicine burden. 
The LMQ-3 demonstrated adequate construct validity and 
was appropriately related to other instruments designed to 
measure relevant constructs, being negatively related to 
treatment satisfaction. Differences in medicine burden were 
shown in relation to key factors, in particular frequency of 
daily use and need for support with using medicines, and the 
instrument may also have acceptable test–retest reliability, 
although this requires confirmation in other studies. The eight 
domains incorporate all the issues covered by the previous 













Lack of effectiveness 0.628 0.376 0.424 0.571
Side-effect burden 0.414 0.597 0.449 0.516
3UDFWLFDOGLIÀFXOWLHV 0.367 0.405 0.529 0.426
Patientdoctor communication problems 0.476 0.278 0.360 0.394
Cost-burden 0.141 0.193 0.157 0.232
General concerns 0.406 0.469 0.401 0.410
Interferences with life 0.360 0.560 0.451 0.430
Lack of autonomy 0.139 0.010* 0.057* 0.121
LMQ-3 total score 0.554 0.623 0.564 0.616
Notes:&RUUHODWLRQVQRWVWDWLVWLFDOO\VLJQLÀFDQWDWp<6SHDUPDQ·VFRUUHODWLRQFRHIÀFLHQWFRUUHODWLRQVLQEROGLQGLFDWHVWURQJHVWDVVRFLDWLRQV
Abbreviations: LMQ-3, Living with Medicines Questionnaire version 3; TSQM-II, Treatment Satisfaction Questionnaire with Medication.
Table 4 Known-groups validity of the LMQ-3
Characteristics Mean LMQ-3  
total score (SD)
(N=336) p-value
Age (years) 1829 104.6 (18.4)
3049 108.4 (22.4)
5064 102.8 (20.5)
≥65 98.4 (17.5) 0.007
Employment Employed 103.2 (20.1)
Unemployed 118.0 (21.5)
Retired 98.3 (17.3) <0.001
No of medicines 14 100.3 (17.7)
59 107.8 (23.8)
≥10 104.4 (20.3) 0.010
Frequency of use Once daily 97.8 (16.0)
Twice daily 101.7 (20.0)
Three times daily 111.4 (23.8)
≥4 times daily 112.7 (22.1) <0.001
Managing medicines Independent 100. 8 (19.5)




Yes 106.2 (20.3) 0.014
Abbreviation: LMQ-3, Living with Medicines Questionnaire version 3.
version, with the exception of a domain relating  specifically 
to communication with pharmacists. The inclusion of cost-
related burden in this revised version was relevant as dem-
onstrated by its clear association with paying prescription 
charges. Side effects were strengthened within this version 
into a separate domain and proved to be one of those most 
strongly associated with overall medicine burden, in addi-
tion to interferences with daily life and general concerns. 
The autonomy domain was less internally consistent and 
also loaded less well on the overall burden construct in the 
second-order model. Our decision to retain it was based on 
the need for this domain identified in the original qualita-
tive interviews on which the instrument was based.20 These 
interviews found that some people feel powerless to change 
their regimen and feel constrained as a result,20 while others 
consider the decision whether or not to take any particular 
medicine is theirs alone. Given that this is fundamental 
to patient-centered medicine optimization, the autonomy 
domain was essential to the instrument. 
It was notable that total LMQ-3 scores were not strongly 
related to age and their relationship with the number of 
medicines was not linear. This suggests that the medicine 
burden for individuals is dependent on a range of factors, 
and that neither age nor the number of medicines alone is 
likely to identify those in need of greater support. Indeed, the 
frequency with which medicines were administered and the 
need for support appeared to show relationships with overall 
burden. As with general treatment burden, any individual’s 
perception of the extent of their own medicine burden will 
depend on social circumstances and coping skills. However, 
there was a positive relationship between total LMQ-3 scores 
and VAS-burden score, suggesting that the instrument does 
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Living with Medicines Questionnaire version 3
Strengths and limitations
The LMQ instrument was developed from the patient per-
spective and the modifications made which resulted in this 
revised version also used only material derived from and 
tested by users of long-term medicines. The data used for 
item generation were drawn from previous studies carried 
Figure 3 Number of missing responses to LMQ questions.
Abbreviations: LMQ, Living with Medicines Questionnaire; Q, question.
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out in 2008 and 2014 and international literature published 
over several decades, thus covering issues of international 
and ongoing significance to medicine users. 
The development and three stages of testing adhered 
to standard guidelines for patient-reported outcome 
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members of the public and patients, recruited using a range of 
methods from different areas across England and in different 
health care settings. The overall population included people 
aged from 18 to 92 years, using between 1 and 26 medicines 
regularly, with varying frequency of medicines administra-
tion and diverse formulations, some who have assistance in 
Table 5 Items with more than 2% missing data in Stage 2




Q5 I worry about paying for my medicines. 34 8.1
Q33 I have to pay more than I can afford for my medicines. 23 5.5
Q31 I sometimes have to choose between buying basic essentials or medicines. 16 3.9
Q37 My medicines interfere with my sexual life. 15 3.6
Q39 My medicines are working. 15 3.6
Q28 Taking medicines affects my driving. 14 3.3
Q30 The side effects I get from my medicines are bothersome. 11 2.6
Q38 The side effects I get from my medicines adversely affect my well-being. 11 2.6
Q29 ,ÀQGXVLQJP\PHGLFLQHVGLIÀFXOW 10 2.4
Q34 The health professionals providing my care know enough about me and my medicines. 10 2.4
Q40 7KHVLGHHIIHFWVDUHZRUWKLWIRUWKHEHQHÀWV,JHWIURPP\PHGLFLQHV 10 2.4






Gender Female 148 (47) 38 (49)
Male 186 (51) (n=316) 168 (53) (n=78) 0.801
Age group (years) 1829 45 (13) 6 (7)
3049 77 (23) 4 (5)
5064 99 (36) 19 (22)
≥65 114 (34) (n=335) 56 (66) (n=85) <0.001
Education level School 115 (36) 43 (57)
Technical college 98 (31) 19 (25)
University 81 (26) 8 (11)
Other 22 (7) (n=316) 17 (8) (n=76) 0.004
Employment status Employed 142 (43) 17 (21)
Unemployed 39 (12) 5 (6)
Retired 129 (39) 58 (72)
Full-time student 19 (6) 1 (1)
Other 0 (n=329) 0 (n=81) <0.001
Ethnicity White 276 (84) 77 (95)
Asian/Asian British 14 (4) 1 (1)
Mixed 9 (3) 1 (1)
Black/African/Caribbean 25 (8) 1 (1)
Other 3 (1) (n=327) 1 (1) (n=81) 0.118
Number of medicines 14 201 (61) 35 (41)
59 93 (28) 33 (39)
≥10 37 (11) (n=331) 17 (20) (n=85) 0.004
Formulation used Tablets/capsules 299 (92) 75 (95)
Any other formulation 26 (8) (n=325) 4 (5) (n=79) 0.683
Frequency of medicine use Once daily 121 (37) 25 (31)
Twice daily 101 (31) 35 (43)
Three times daily 39 (12) 10 (12)
≥4 times daily 41 (13) 6 (7)
Other times 23 (7) (n=325) 5 (6) (n=81) 0.269
Assisted in using 
medicines
No - independent 286 (87) 63 (79)
Yes - has a caretaker 41 (13) (n=327) 17 (21) (n=80) 0.051
Pays for prescriptions No 203 (62) 64 (80)
Yes 125 (38) (n=328) 16 (20) (n=80) 0.002
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Living with Medicines Questionnaire version 3
managing medicines, and some who contribute to paying for 
medicines. Stage 1 respondents were drawn from the whole 
of England, whereas those in Stages 2 and 3 were from South 
East England. However, we have no reason to suppose that 
patients and members of the public in the South East dif-
fer from those across the rest of England in their medicine 
experiences. The majority of respondents in Stages 1 and 
3, which required access to the Internet, were female, and 
the samples were biased toward those with higher education 
levels. In contrast, males were well represented in Stage 2, 
with respondents also being older and less highly educated. 
However, the frail or housebound may have been excluded 
from this stage by virtue of the recruitment methods used. 
There is no gold standard for measuring medicine burden; 
hence, we used treatment satisfaction and HRQoL measures 
to assess criterion validity and confirmed that the LMQ 
measures a distinct concept. Test–retest assessment assumed 
that the sample population studied was stable in terms of 
their prescription medicine use experiences, hence medicine 
burden, and was not large enough to confirm this aspect of 
the instrument. Moreover, the length of the instrument is a 
potential barrier to completion, and some questions may be 
perceived as of no direct relevance to some individuals. The 
items covering cost and some social impacts, which this 
revised instrument was designed to incorporate, may thus 
need to include alternative responses. 
Relevance to research and practice
Other measures of treatment burden either focus on indi-
vidual disease states or involve aspects of care beyond 
medicines,4,13 but many of the domains and issues included 
in these instruments are similar to those covered by the 
LMQ-3. This suggests that the LMQ-3, as a generic measure 
of medicine use, may be particularly useful as a patient-
reported outcome measure in studies designed to reduce the 
burden of polypharmacy in patients with multimorbidity. 
The finding that the relationship between medicine burden 
and the number of medicines is not clear-cut is important 
for practice. As has been found by others, some individu-
als may be burdened by relatively few medicines, while 
others do not perceive large quantities of medicines to be 
burdensome.4,12,38,39 Current guidelines produced by National 
Institute for Health and Care Excellence on multimorbidity 
suggest that the number of regular medicines prescribed is 
used as a marker of increased treatment burden and suggests 
using an approach which takes into account multimorbidity 
for those prescribed 10 or more regular medicines or those 
prescribed fewer than 10 regular medicines who are at par-
ticular risk of adverse events.40
Further work to confirm reliability, assess sensitivity to 
change, and to determine whether greater perceived burden 
relates to adherence and clinical outcomes is desirable. To 
date, the LMQ-3 has been successfully translated into Ara-
bic41 and is also being used in studies in several other coun-
tries, which will contribute to obtaining a fuller picture of the 
usefulness of this instrument and provide comparative data 
on the burden of using long-term medicines across settings.
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